Ozmosi | CT-P10 Drug Profile

Product Description

CT-P10 (Truximaª) is the first biosimilar of the reference monoclonal anti-CD20 antibody rituximab. It is approved for use in all indications for which reference rituximab is approved, including follicular lymphoma (FL), diffuse large B-cell non-Hodgkin's lymphoma, chronic lymphocytic leukaemia, rheumatoid arthritis (RA), granulomatosis with polyangiitis and microscopic polyangiitis (Sourced from: https://pubmed.ncbi.nlm.nih.gov/28497220/)

Mechanisms of Action: CD20 Antagonist

Novel Mechanism: No

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Celltrion
Company Location:
Company Founding Year: None
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success	Latest Trial Update Date	Data Updated
ACTRN12622000306718p	2006-7041-83/hah	N/A	Not yet recruiting	Dental Caries\|Intestinal Diseases	2022-02-28
NCT05052528	UCDCC#299	P1	Recruiting	Diffuse Large B-Cell Lymphoma	2025-05-15		2024-05-14
NCT02960646	NCI-2016-01915	P1	Completed	Chronic Myelomonocytic Leukemia\|Acute Myeloid Leukemia\|Acute Myelomonocytic Leukemia\|Anemia, Aplastic\|Lymphocytic Chronic B-Cell Leukemia\|Acute Lymphoid Leukemia\|Chronic Myeloid Leukemia\|Blast Crisis\|Juvenile Myelomonocytic Leukemia,\|Myelodysplastic Syndrome\|Preleukemia\|Lymphoma, Non-Hodgkin\|Myeloproliferative Disorders\|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma\|Precursor Cell Lymphoblastic Leukemia-Lymphoma\|Multiple Myeloma\|Acute Monocytic Leukemia\|Myelogenous, Chronic, BCR-ABL Positive Leukemia\|Chronic Lymphoid Leukemia\|Lymphoma, B-Cell\|Leukemia, Plasma Cell	2023-02-13		2023-02-18	Primary Completion Date\|Primary Endpoints\|Study Completion Date\|Treatments\|Trial Status
NCT03432741	MC1689	P1	Terminated	T-Cell Cutaneous Lymphoma\|B-Cell Marginal Zone Lymphoma\|Mycosis Fungoides\|Lymphoma, Non-Hodgkin\|Breast Cancer\|Adenocarcinoma	2022-08-26		2025-05-28	Primary Completion Date\|Primary Endpoints\|Treatments
NCT01619761	NCI-2012-02071	P1	Unknown status	Acute Myeloid Leukemia\|Biphenotypic Acute Leukemia\|Acute Lymphoid Leukemia\|Leukemia, Plasma Cell\|Lymphoma, B-Cell\|Myelodysplastic Syndrome\|Chronic Myeloid Leukemia\|Precursor Cell Lymphoblastic Leukemia-Lymphoma\|Myeloid, Accelerated Leukemia\|Chronic Lymphoid Leukemia\|Lymphocytic Chronic B-Cell Leukemia\|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma\|Preleukemia\|Lymphoma, Non-Hodgkin\|Multiple Myeloma\|Myelogenous, Chronic, BCR-ABL Positive Leukemia	2021-11-01		2022-02-02	Primary Endpoints\|Treatments\|Trial Status
NCT02779283	IRB00011766	P1	Completed	Acute Lymphoid Leukemia\|Acute Myeloid Leukemia\|Precursor Cell Lymphoblastic Leukemia-Lymphoma	2018-04-19		2025-02-07	Primary Endpoints\|Treatments
NCT01873443	CT-P10 1.3	P1	Completed	Arthritis, Rheumatoid	2014-10-01		2019-03-19	Treatments
NCT02727803	NCI-2016-00584	P2	Recruiting	Acute Myeloid Leukemia\|Leukemia, Plasma Cell\|Acute Myelomonocytic Leukemia\|Myelogenous, Chronic, BCR-ABL Positive Leukemia\|Myelodysplastic Syndrome\|B-Cell Leukemia\|Preleukemia\|Anemia, Refractory, with Excess of Blasts\|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma\|Biphenotypic Acute Leukemia\|Lymphoma, B-Cell\|Myelodysplastic-Myeloproliferative Diseases\|Acute Lymphoid Leukemia\|Chronic Lymphoid Leukemia\|Multiple Myeloma\|Acute Monocytic Leukemia\|Myeloid, Accelerated Leukemia\|Lymphoma, Non-Hodgkin\|Chronic Myeloid Leukemia\|Juvenile Myelomonocytic Leukemia,\|Chronic Myelomonocytic Leukemia\|Precursor Cell Lymphoblastic Leukemia-Lymphoma\|Myeloproliferative Disorders	2027-05-31		2025-05-10	Primary Completion Date\|Primary Endpoints\|Study Completion Date\|Treatments
NCT06834373	MC230813	P2	Recruiting	Lymphoma, Non-Hodgkin\|Inflammation\|Follicular Lymphoma\|Diffuse Large B-Cell Lymphoma\|T-Cell Cutaneous Lymphoma	2027-03-03		2025-04-05	Primary Endpoints\|Start Date\|Treatments\|Trial Status
NCT03096782	NCI-2018-01236	P2	Completed	Acute Myelomonocytic Leukemia\|Chronic Lymphoid Leukemia\|Juvenile Myelomonocytic Leukemia,\|Lymphocytic Chronic B-Cell Leukemia\|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma\|Precursor Cell Lymphoblastic Leukemia-Lymphoma\|Myeloid, Accelerated Leukemia\|Lymphoma, B-Cell\|Acute Lymphoid Leukemia\|Hodgkin Lymphoma\|Chronic Myelomonocytic Leukemia\|Lymphoma, Non-Hodgkin\|Acute Myeloid Leukemia\|Preleukemia\|Myelogenous, Chronic, BCR-ABL Positive Leukemia\|Histiocytosis, Langerhans-Cell\|Chronic Myeloid Leukemia\|Anemia, Refractory, with Excess of Blasts\|Myelodysplastic Syndrome\|Acute Monocytic Leukemia\|Biphenotypic Acute Leukemia	2022-09-20		2023-06-30	Primary Endpoints
NCT05457556	ASCT2031	P3	Active, not recruiting	Preleukemia\|Acute Myeloid Leukemia\|Acute Lymphoid Leukemia\|Precursor Cell Lymphoblastic Leukemia-Lymphoma\|Myelodysplastic Syndrome	2026-06-30		2025-05-06	Primary Completion Date\|Primary Endpoints\|Study Completion Date\|Treatments\|Trial Status
NCT02003222	NCI-2013-02229	P3	Active, not recruiting	Precursor Cell Lymphoblastic Leukemia-Lymphoma\|Acute Lymphoid Leukemia	2023-06-23		2025-02-07	Primary Endpoints\|Treatments
2014-005324-10	2014-005324-10	P3	Completed	Follicular Lymphoma	2019-09-04		2025-05-06	Treatments
2013-004493-96	2013-004493-96	P3	Completed	Follicular Lymphoma	2018-12-29		2022-03-13	Treatments
NCT02260804	CT-P10 3.4	P3	Completed	Follicular Lymphoma	2018-01-04	42%	2021-04-09	Patient Enrollment\|Primary Completion Date\|Primary Endpoints\|Start Date\|Study Completion Date\|Treatments\|Trial Status
NCT02162771	rituximab	P3	Completed	Follicular Lymphoma	2016-01-12		2020-01-30	Patient Enrollment\|Primary Completion Date\|Start Date\|Study Completion Date
NCT02149121	rituximab	P3	Completed	Arthritis, Rheumatoid	2016-01-01		2021-12-17	Primary Endpoints\|Treatments
2011-002813-12	2011-002813-12	P3	Terminated	Follicular Lymphoma	2013-09-30		2022-03-13	Treatments

Recent News Events

Date	Type	Title
06/23/2023	PubMed	Transcriptome Profiling of Vero E6 Cells during Original Parental or Cell-Attenuated Porcine Epidemic Diarrhea Virus Infection.
04/01/2023	PubMed	Interchangeability and adverse events in originator-rituximab and its biosimilar (CT-P10) among rheumatic patients: a real-life experience.
11/06/2022	PubMed	Real-world clinical effectiveness and safety of CT-P10 in patients with diffuse large B-cell lymphoma: An observational study in Europe.
04/14/2021	News Article	Global Biosimilar Monoclonal Antibodies Forecast 2020-2030
04/10/2020	News Article	Visiongain Report Provides Critical Market-led Data on the $6.6bn Biosimilar Monoclonal Antibodies Market
07/18/2019	News Article	Celltrion and Nan Fung Group to establish Vcell Healthcare Limited to Develop and Commercialize Biosimilars in China

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

CT-P10

Alternative Names: ct-p10, ctp10, ct p10 Clinical Status: Inactive Latest Update: 2026-02-10 Latest Update Note: Clinical Trial Update